Oct 2 |
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
|
Sep 23 |
Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
|
Sep 13 |
Arcus up 4% following Merck Welireg kidney cancer data
|
Sep 10 |
Arcus Biosciences Announces New Employment Inducement Grants
|
Aug 28 |
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
|
Aug 27 |
Arcus Biosciences secures $250M term loan facility
|
Aug 27 |
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
|
Aug 16 |
Nuntius partners with Taiho to develop mRNA cancer therapies
|
Aug 10 |
Arcus Biosciences Second Quarter 2024 Earnings: Beats Expectations
|
Aug 10 |
We're Not Very Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Rate
|